Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,487 matching trials from the live ClinicalTrials.gov search.

Filters: Evanston, Illinois Clear all

Conditions: SARS-CoV-2 Infection
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 25 Years
Enrollment: 15,028 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 51 more

Conditions: Lung Disease, Lung Ultrasound
Interventions: Lung ultrasound; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 22 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Chicago, Illinois • Evanston, Illinois

Conditions: Cervical Cancer
Interventions: oxaliplatin; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 60 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 91
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more

Conditions: Covid19
Interventions: Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 10,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 110
States / cities: Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: dolastatin 10; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 11
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more

Conditions: Metastatic Pancreatic Cancer
Interventions: Albumin-bound paclitaxel (ABI-007), Gemcitabine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 90
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 71 more

Conditions: Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions: Tigecycline, Ertapenem; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: Los Angeles, California • Northridge, California • San Francisco, California + 20 more

Conditions: Interstitial Cystitis
Interventions: Pentosan polysulfate sodium 100 mg, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 52
States / cities: Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 49 more

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: BION-1301, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more

Conditions: Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracerebral Haemorrhage
Interventions: Early Surgical Hematoma Evacuation; Procedure
Lead sponsor: Nico Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Colorectal Cancer
Interventions: cyclosporine, CPT-11; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 10
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: afatinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 66
States / cities: Mobile, Alabama • Goodyear, Arizona • Hot Springs, Arkansas + 59 more

Conditions: Crohn's Disease
Interventions: PF-04236921; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 62
States / cities: Scottsdale, Arizona • Tucson, Arizona • Lakewood, Colorado + 30 more

Conditions: Intracranial Aneurysm
Interventions: Penumbra Smart Coil, Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD); Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: Not listed
Enrollment: 995 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Dothan, Alabama • Mesa, Arizona • Phoenix, Arizona + 62 more

Conditions: Cervical Cancer
Interventions: cisplatin, paclitaxel, brachytherapy, radiation therapy; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 31
States / cities: Phoenix, Arizona • Newark, Delaware • Chicago, Illinois + 26 more

Conditions: Cancer
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 112
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more

Conditions: Cardiovascular Disease
Interventions: Febuxostat, Allopurinol; Drug
Lead sponsor: Takeda; Industry
Eligibility: 50 Years and older
Enrollment: 6,198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 202
States / cities: Decatur, Georgia • Dunwoody, Georgia • Marietta, Georgia + 199 more

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Interventions: Laboratory Biomarker Analysis, Selumetinib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 16
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 12 more

Conditions: Respiratory Syncytial Virus Hospitalizations
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Up to 12 Months
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 44
States / cities: Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 40 more

Conditions: Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: stereotactic radiosurgery, whole-brain radiation therapy; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 37
States / cities: Burlingame, California • Los Angeles, California • Newark, Delaware + 30 more

Conditions: Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Interventions: MEDI4736, MEDI4736 + Tremelimumab, Standard of Care; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 23
States / cities: Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more

Conditions: Wound Complication, Complications; Cesarean Section
Interventions: Tissue Adhesive, Sterile strips; Device
Lead sponsor: Endeavor Health; Other
Eligibility: Female only
Enrollment: 504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • Highland Park, Illinois

Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Neratinib Maleate, Palbociclib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 154 more

Search by objective public record fields.

Understanding the Long-term Impact of COVID on Children and Families

Point of Care Lung Ultrasound Examination in Patients With Shortness of Breath

Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

ACTIV-6: COVID-19 Study of Repurposed Medications

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis

A Study of Zigakibart in Adults With IgA Nephropathy

ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Afatinib Expanded Access Program

B0151005 Open-Label Extension Study

Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Tissue Adhesive vs. Sterile Strips After Cesarean Delivery

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)